TY - JOUR
T1 - An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution
AU - Gil-Etayo, Francisco Javier
AU - Garcinuño, Sara
AU - Utrero-Rico, Alberto
AU - Cabrera-Marante, Oscar
AU - Arroyo-Sanchez, Daniel
AU - Mancebo, Esther
AU - Pleguezuelo, Daniel Enrique
AU - Rodríguez-Frías, Edgard
AU - Allende, Luis M.
AU - Morales-Pérez, Pablo
AU - Castro-Panete, María José
AU - Lalueza, Antonio
AU - Lumbreras, Carlos
AU - Paz-Artal, Estela
AU - Serrano, Antonio
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2
Y1 - 2022/2
N2 - The Th1/Th2 balance plays a crucial role in the progression of different pathologies and is a determining factor in the evolution of infectious diseases. This work has aimed to evaluate the early, or on diagnosis, T-cell compartment response, T-helper subsets and anti-SARS-CoV-2 antibody specificity in COVID-19 patients and to classify them according to evolution based on infection severity. A unicenter, randomized group of 146 COVID-19 patients was divided into four groups in accordance with the most critical events during the course of disease. The immunophenotype and T-helper subsets were analyzed by flow cytometry. Asymptomatic SARS-CoV-2 infected individuals showed a potent and robust Th1 immunity, with a lower Th17 and less activated T-cells at the time of sample acquisition compared not only with symptomatic patients, but also with healthy controls. Conversely, severe COVID-19 patients presented with Th17-skewed immunity, fewer Th1 responses and more activated T-cells. The multivariate analysis of the immunological and inflammatory parameters, together with the comorbidities, showed that the Th1 response was an independent protective factor for the prevention of hospitalization (OR 0.17, 95% CI 0.03–0.81), with an AUC of 0.844. Likewise, the Th1 response was found to be an independent protective factor for severe forms of the disease (OR 0.09, 95% CI: 0.01–0.63, p = 0.015, AUC: 0.873). In conclusion, a predominant Th1 immune response in the acute phase of the SARS-CoV-2 infection could be used as a tool to identify patients who might have a good disease evolution.
AB - The Th1/Th2 balance plays a crucial role in the progression of different pathologies and is a determining factor in the evolution of infectious diseases. This work has aimed to evaluate the early, or on diagnosis, T-cell compartment response, T-helper subsets and anti-SARS-CoV-2 antibody specificity in COVID-19 patients and to classify them according to evolution based on infection severity. A unicenter, randomized group of 146 COVID-19 patients was divided into four groups in accordance with the most critical events during the course of disease. The immunophenotype and T-helper subsets were analyzed by flow cytometry. Asymptomatic SARS-CoV-2 infected individuals showed a potent and robust Th1 immunity, with a lower Th17 and less activated T-cells at the time of sample acquisition compared not only with symptomatic patients, but also with healthy controls. Conversely, severe COVID-19 patients presented with Th17-skewed immunity, fewer Th1 responses and more activated T-cells. The multivariate analysis of the immunological and inflammatory parameters, together with the comorbidities, showed that the Th1 response was an independent protective factor for the prevention of hospitalization (OR 0.17, 95% CI 0.03–0.81), with an AUC of 0.844. Likewise, the Th1 response was found to be an independent protective factor for severe forms of the disease (OR 0.09, 95% CI: 0.01–0.63, p = 0.015, AUC: 0.873). In conclusion, a predominant Th1 immune response in the acute phase of the SARS-CoV-2 infection could be used as a tool to identify patients who might have a good disease evolution.
KW - COVID-19
KW - Cell mediated immunity
KW - Imbalanced immune response
KW - SARS-CoV2
KW - T helper
KW - T-cell subsets
KW - Th1
KW - Th17
KW - Th2
UR - https://www.scopus.com/pages/publications/85123574350
U2 - 10.3390/biomedicines10020296
DO - 10.3390/biomedicines10020296
M3 - Article
AN - SCOPUS:85123574350
SN - 2227-9059
VL - 10
JO - Biomedicines
JF - Biomedicines
IS - 2
M1 - 296
ER -